Loading...

CRNX CRINETICS PHARMACEUTICALS INC Expansion Plans 8-K Filing

CRNT

CRNX

CRINETICS PHARMACEUTICALS INC

(CRNX)

2026 8-K

Financial Results Report

Management Change

Management Change

Accountant Change

Financial Results Report

Management Change

Financial Update

Stock Offering Announcement

Financial Results Update

Leadership Change

Financial Results Report

FDA Approval Announcement

Financial Statements

Product Expansion

Financial Statements

Management Change

Financial Results

Management Change

Positive Study Results

Management Change

FDA Drug Approval

Financial Results

Management Change

New Drug Application

Management Change

Financial Results and CFO D...

Sales Agreement

Positive Findings from Deve...

Financial Results

Conference Presentation

Management Plan Approval

Phase 3 Study Results

Phase 2 Study Results

Securities Purchase Agreeme...

Financial Results

J.P. Morgan Healthcare Conf...

Positive Phase 2 Study Find...

Amendments to Bylaws

Financial Results

Underwriting Agreement

Phase 3 Study Results

Earnings Reports

Annual Meeting Results

Financial Results

Closure of Silicon Valley B...

Financial Results

J.P. Morgan Healthcare Conf...

External Links:

On January 13, 2026, Crinetics Pharmaceuticals reported that it generated over $5.0 million in net product revenue from their drug PALSONIFY for the fourth quarter of 2025. This filing is significant as it provides preliminary insights into the company’s financial performance and plans, highlighting their participation in the J.P. Morgan Healthcare Conference.

AI Assistant

CRINETICS PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.